Antibody Response Six Months after SARS-CoV-2 mRNA Vaccination in Patients with Inflammatory Bowel Disease

Clin Gastroenterol Hepatol. 2022 Jul;20(7):1609-1612.e1. doi: 10.1016/j.cgh.2021.12.045. Epub 2022 Jan 6.


Patients with inflammatory bowel disease (IBD) are recommended to receive vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), regardless of their immunosuppression status. Immunosuppressive medications represent a mainstay of therapy in moderate to severe IBD; however, their impact on the SARS-CoV-2 vaccine response remains unclear. Studies thus far have shown that patients with IBD on various therapies had detectable antibody responses after standard vaccinations.1-5 To date, one study has examined the kinetics of antibody response at 3 months after vaccination in patients with IBD, but data beyond this time point are not yet available.6 The aim of this study was to assess anti-spike antibody response 6 months after completion of standard SARS-CoV-2 vaccination in patients with IBD. Secondarily, we observed antibody kinetics over 6 months in a subset of patients post-vaccination.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural
  • Letter

MeSH terms

  • Antibody Formation
  • COVID-19 Vaccines
  • COVID-19* / prevention & control
  • Humans
  • Inflammatory Bowel Diseases* / drug therapy
  • RNA, Messenger
  • SARS-CoV-2
  • Vaccination
  • Viral Vaccines* / genetics


  • COVID-19 Vaccines
  • RNA, Messenger
  • Viral Vaccines